Outcomes Research Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data. Our data warehouse is the largest in the outpatient infusion industry. Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. Additionally, the strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research. Here is an example of one of our class-leading studies enabled by our data: Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs) Lucinda J. Van Anglen, PharmD Thomas C. Hardin, PharmD, Claudia P. Schroeder, PharmD, PhD Open Forum Infect Dis (Fall 2018) 5 (suppl1): doi:10.1093/ofid/ofy210.2020 All Related Studies COST SAVINGS & LOWER RESOURCE UTILIZATION Our studies demonstrate that the physician office site of care provides significantly lower total costs compared to other settings. The Healix site of care program allows our external partners to maximize these cost benefits. Successful Early Discharge and Avoided Hospitalization for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Treated with Outpatient Parenteral Antimicrobial Therapy (OPAT) Result in Healthcare Cost Savings Presented on October 24, 2016 Robin H. Dretler, MD, FIDSA Quyen Luu, MD Richard C. Prokesch, MD, FACP, FIDSA Andrew H. Krinsky, MD H. Barry Baker, MD, FACP Claudia P. Schroeder, PharmD, PhD Lucinda J. Van Anglen, PharmD A 2-Year Analysis of 30-Day Hospital Readmissions and Cost Benefits of Septicemia Outpatient Treatment in a Physician Office Infusion Center (POIC) Presented on October 7, 2015 Barry Statner, MD, CM FRCPC, FIDSA Fernando S. Alvarado, MD, MPH, TM Brian Metzger, MD, MPH Richard M. Mandel, MD, FIDSA Jorge R. Bernett, MD H. Barry Baker, MD, FACP Alfred E. Bacon III, MD Claudia P. Schroeder, PharmD, PhD Lucinda J. Van Anglen, PharmD Open Forum Infect Dis (Fall 2015) 2 (suppl 1): doi:10.1093/ofid/ofv133.1017 Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs. Traditional Home Health Care (HHC) Presented on October 8, 2014 Richard C. Prokesch, MD, FACP, FIDSA John S. Adams, MD, FIDSA Ramesh V. Nathan, MD Claudia P. Schroeder, PharmD Lucinda J. Van Anglen, PharmD K. Dale Hooker, PharmD Cost Savings Utilizing Outpatient Parenteral Antimicrobial Therapy (OPAT) for Treatment of Complicated Skin and Skin Structure Infections (cSSSI) in Physician Operated Infusion Centers (POICs) without Hospitalization Presented on October 27, 2009 Lucinda J. Van Anglen, PharmD Michael P. Dailey, MD Andrew H. Krinsky, MD John S. Adams, MD All Related Studies CLINICAL OUTCOMES Our physicians and clinical teams enable outstanding clinical outcomes in the physician office setting. Publication: Outpatient Treatment of Osteomyelitis with Telavancin Published July 2017 Claudia P. Schroeder, PharmD, PhD Lucinda J. Van Anglen, PharmD Robin H. Dretler, MD John S. Adams, MD, FIDSA, FSHEA Richard C. Prokesch, MD, FACP, FIDSA Quyen Luu, MD Andrew H. Krinsky, MD (doi: 10.1016/j.ijantimicag.2017.01.034). It appears in The International Journal of Antimicrobial Agents, Volume 50, Issue 1, 93 – 96 (2017), published by Elsevier Outpatient Treatment of Infective Endocarditis at Physician Office Infusion Centers (POICs): A 2-Year Analysis of Clinical and Economic Outcomes Presented on October 24, 2016 Brian S. Metzger, MD, MPH Richard M. Mandel, MD, FIDSA Jorge R. Bernett, MD Barry Statner, MD, FRCPC, FIDSA John S. Adams, MD, FIDSA, FSHEA Alfred E. Bacon, III, MD Kimberly Couch, PharmD, MA, FIDSA, FASHP Claudia P. Schroeder, PharmD, PhD Lucinda J. Van Anglen, PharmD Open Forum Infect Dis (Fall 2016) 3 (suppl 1): doi:10.1093/ofid/ofw172.823 Real-World Comparison of Arthralgias with Infliximab vs. Vedolizumab in the Treatment of Bio-Naïve Inflammatory Bowel Disease Presented on January 23, 2020 Timothy E. Ritter, MD Chris Fourment, MD Samantha A. Mehta, PharmD Lucinda J. Van Anglen, PharmD CCFA 2020 #P100 Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) Treated in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis Presented on November 26, 2018 Brian S. Metzger, MD, MPH John S. Adams, MD, FIDSA, FSHEA Jorge R. Bernett, MD Richard M. Mandel, MD, FIDSA Richard C. Prokesch, MD, FACP, FIDSA Carson T. Lo, MD Thomas C. Hardin, PharmD Claudia P. Schroeder, PharmD, PhD Lucinda J. Van Anglen, PharmD Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093/ofid/ofy210.324 All Related Studies SPECIAL POPULATIONS Real-World Experience of Vedolizumab in Pediatric Inflammatory Bowel Disease Presented on October 5, 2018 Annette E. Whitney, MD Harry E. Sarles, Jr., MD, FACG Claudia P. Schroeder, PharmD, PhD Tracy C. Okoro, PharmD Lucinda J. Van Anglen, PharmD Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population Presented on October 4, 2017 Lucinda J. Van Anglen, PharmD Richard M. Mandel, MD, FIDSA Ramesh V. Nathan, MD, FIDSA Andrew H. Krinsky, MD Quyen Luu, MD Alfred E. Bacon, III, MD H. Barry Baker, MD, FACP Claudia P. Schroeder, PharmD, PhD Kimberly A. Couch, PharmD All Related Studies PERSISTENCE Our clinicians achieve better medication adherence through our high-touch model than any other setting. Tolerability and Persistence with Subcutaneous Immunoglobulin Provided Through Physician Clinics for the Treatment of Primary Immunodeficiencies Presented on February 22, 2019 Richard F. Herrscher, MD, FACAAI Tidence L. Prince, MD Lucinda J. Van Anglen, PharmD Claudia P. Schroeder, PharmD, PhD All Related Studies NEW THERAPIES AND PROGRAMS Effective Antimicrobial Stewardship for Outpatient Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Diseases Physician Infusion Centers Presented on November 26, 2018 Ramesh V. Nathan, MD Richard L. Hengel, MD Andrew H. Krinsky, MD Thomas K. Sleweon, MD Alfred E. Bacon III, MD Dale Hooker, PharmD Claudia P. Schroeder, PharmD, PhD Kimberly A. Couch, PharmD, MA Lucinda J. Van Anglen, PharmD Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093.ofid/ofy210.1510 Evaluation of Bezlotoxumab in Prevention of Recurrent C. Difficile Infection: A multicenter Single-Arm Study in Office Infusion Centers Presented on October 3, 2018 Richard L. Hengel, MD Timothy E. Ritter, MD Ramesh V. Nathan, MD, FIDSA Lucinda J. Van Anglen, PharmD Stephen W. Marcella Kevin W. Garey, Pharm.D., M.S., FASHP Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093/ofid/ofy210.510 Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers Presented on November 26, 2018 Quyen Luu, MD Barry Statner, MD, FRCPC, FIDSA Robin H. Dretler, MD, FIDSA H. Barry Baker, MD, FACP Brian S. Metzger, MD, MPH Thomas C. Hardin, PharmD Claudia P. Schroeder, PharmD, PhD Lucinda J. Van Anglen, PharmD Open Forum Infect Dis (Fall 2018) 5 (suppl 1): doi: 10.1093/ofid/ofy210.2033 Phase II And Phase III Studies Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease. For information on partnering with Healix on a study, please contact us. Contact usPrivacy PolicyTerms and conditionsADP employee loginClient loginPaycom Employee Login web design © Healix Infusion Therapy